Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
AOTI, Inc. (AOTI.L)
Oceanside, US
AOTI, Inc. specializes in creating and marketing healthcare technologies specifically designed for treating persistent and hard-to-heal wounds. Among its offerings are the innovative Topical Wound Oxygen (TWO2) Therapy and the NEXA Negative Pressure Wound Therapy (NPWT) System. Michael Stephen Griffiths founded the company in 2006, and its main office is located in Oceanside, California.
No mergers or acquisitions recorded for this company.
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| +0.00% | -3.03% | +66.23% | +52.38% | +70.67% | +132.73% | -20.00% | -52.94% | -52.94% | -52.94% | -52.94% |
Revenue flow
Revenue by geography
Revenue by segment
Revenue composition
By product
By geography
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
DCF figures are point estimates: small changes in growth or discount-rate assumptions move them materially. Read them as a reference, not a precise target.
| Rating | 2026-05 | Change |
|---|---|---|
| Strong Buy | 0 | 0 |
| Buy | 2 | 0 |
| Hold | 0 | 0 |
| Sell | 0 | 0 |
| Strong Sell | 0 | 0 |
-
Revenue growth Medical - Specialties: +8.3%+32.9% ★ Q2'25: +547.8% (vs Q2'23)
-
EPS growth Medical - Specialties: +10.1%-302.4% Q2'25: +137.0% (vs Q2'23)
-
FCF margin FCF growth · Medical - Specialties: +51.3%-23.1% Q2'25: -18.5% (vs Q2'23)
-
EBIT margin Medical - Specialties: +12.6%+1.6% Q2'25: +6.2% (vs Q2'23)
-
ROIC Medical - Specialties: +6.6%+5.3% Q2'25: +14.8% (vs Q2'23)
-
Share dilution Medical - Specialties: 0.0%+0.0% ★ Q2'25: +7.1% (vs Q2'23)
-
Debt / EBITDA Net debt/EBITDA · Medical - Specialties: -0.39×3.38× Q2'25: 2.20× (vs Q2'23)
* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.
| Metric |
Dec 2024 actual |
Dec 2025 actual |
Dec 2026 2 Rev. Ana. 2 EPS Ana. |
Dec 2027 2 Rev. Ana. 2 EPS Ana. |
Dec 2028 1 Rev. Ana. 1 EPS Ana. |
|---|---|---|---|---|---|
| Revenue |
58.36M
est: 58.10M (+0.4%)
|
66.71M
est.
|
73.79M
72.92M – 74.65M
+10.6% YoY
|
93.71M
92.95M – 94.47M
+27.0% YoY
|
99.53M
98.56M – 100.50M
+6.2% YoY
|
| EBITDA |
2.64M
est: 14.55M (-81.9%)
|
16.70M
est.
|
18.47M
18.26M – 18.69M
+10.6% YoY
|
23.46M
23.27M – 23.65M
+27.0% YoY
|
24.92M
24.67M – 25.16M
+6.2% YoY
|
| EBIT |
908.0K
est: 12.75M (-92.9%)
|
14.64M
est.
|
16.19M
16.00M – 16.38M
+10.6% YoY
|
20.57M
20.40M – 20.73M
+27.0% YoY
|
21.84M
21.63M – 22.05M
+6.2% YoY
|
| Net Income |
-1.76M
est: 3.19M (-155.0%)
|
2.26M
est.
|
2.75M
1.32M – 4.18M
+21.4% YoY
|
7.89M
6.93M – 8.86M
+187.3% YoY
|
7.30M
7.21M – 7.39M
-7.5% YoY
|
| SGA |
—
est: 2.95M (-100.0%)
|
3.39M
est.
|
3.75M
3.70M – 3.79M
+10.6% YoY
|
4.76M
4.72M – 4.80M
+27.0% YoY
|
5.05M
5.00M – 5.10M
+6.2% YoY
|
| EPS |
-0.02
est: 0.03 (-155.0%)
|
0.02
est.
|
0.03
0.01 – 0.04
+21.4% YoY
|
0.07
0.07 – 0.08
+187.3% YoY
|
0.07
0.07 – 0.07
-7.5% YoY
|
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-11 | C | 2/5 | 1/5 | 3/5 | 3/5 | 1/5 | 1/5 | 2/5 |
| 2026-05-08 | C | 2/5 | 1/5 | 2/5 | 3/5 | 1/5 | 1/5 | 2/5 |
| 2026-05-07 | C | 2/5 | 1/5 | 2/5 | 3/5 | 1/5 | 1/5 | 2/5 |
| 2026-05-06 | C | 2/5 | 1/5 | 2/5 | 3/5 | 1/5 | 1/5 | 2/5 |
| 2026-05-05 | C | 2/5 | 1/5 | 2/5 | 3/5 | 1/5 | 1/5 | 2/5 |
| 2026-05-01 | C | 2/5 | 1/5 | 2/5 | 4/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-30 | C | 2/5 | 1/5 | 2/5 | 4/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-29 | C | 2/5 | 1/5 | 2/5 | 4/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-28 | C | 2/5 | 1/5 | 2/5 | 4/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-27 | C | 2/5 | 1/5 | 2/5 | 4/5 | 1/5 | 1/5 | 2/5 |
| 2026-04-24 | C | 2/5 | 1/5 | 2/5 | 4/5 | 1/5 | 1/5 | 2/5 |
| 2026-04-23 | C | 2/5 | 1/5 | 2/5 | 4/5 | 1/5 | 1/5 | 2/5 |
| 2026-04-22 | C | 2/5 | 1/5 | 2/5 | 4/5 | 1/5 | 1/5 | 2/5 |
| 2026-04-21 | C | 2/5 | 1/5 | 2/5 | 4/5 | 1/5 | 1/5 | 2/5 |
| 2026-04-20 | C | 2/5 | 1/5 | 2/5 | 4/5 | 1/5 | 1/5 | 2/5 |
| 2026-04-17 | C | 2/5 | 1/5 | 2/5 | 4/5 | 1/5 | 1/5 | 2/5 |
| 2026-04-16 | C | 2/5 | 1/5 | 2/5 | 4/5 | 1/5 | 1/5 | 2/5 |
Owner Earnings
Ownership Overview
Ownership breakdown not available.
No beneficial ownership filings recorded.
Institutional Activity (13F)
Institutional history not available.
Top holders not available.
ETF Ownership
This company is not held by any ETF in our universe.
Insider Activity
No insider activity available.
Insider history not available.
No recent insider transactions.
Executive team
Executive compensation
Executive compensation not available.
No CEO compensation history available.
Proxy statements
No proxy statements available for this company yet.
Recent SEC filings
No SEC filings available for this company yet.
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Michael Griffiths | President, Chief Executive Officer & Director | 448.2K | — |
| Jayesh Pankhania | Chief Financial Officer & Director | 210.5K | male |
| Gina So'oto | Executive Vice President of Global Human Resources | — | female |
| Marty Sylvain | Chief Advocacy Officer | — | male |
| Matthew G. Garoufalis FFPM | Chief Medical Officer | — | — |
| Robbie Walsh | Executive Vice President of Quality & Regulatory Affairs | — | male |
| Darron Daly | Executive Vice President of Marketing & Professional Relations | — | male |
| Stacy Reel | Chief Commercial Officer | — | female |
| David Hammond | President of Commercial International | — | male |
No data available for this company.
No Senate trading activity found for this company.
No House trading activity found for this company.
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for AOTI.L
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
